These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 26063632)
21. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ. Shurell E; Olcese C; Patil S; McCormick B; Van Zee KJ; Pilewskie ML Cancer; 2018 Jan; 124(1):46-54. PubMed ID: 28960259 [TBL] [Abstract][Full Text] [Related]
22. Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe. Wickberg Å; Liljegren G; Killander F; Lindman H; Bjöhle J; Carlberg M; Blomqvist C; Ahlgren J; Villman K Eur J Surg Oncol; 2018 Jul; 44(7):951-956. PubMed ID: 29709338 [TBL] [Abstract][Full Text] [Related]
23. Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases. Cutuli B; De Lafontan B; Kirova Y; Auvray H; Tallet A; Avigdor S; Brunaud C; Delva C Radiat Oncol; 2015 May; 10():110. PubMed ID: 25944033 [TBL] [Abstract][Full Text] [Related]
24. Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy? Pilewskie M; Olcese C; Patil S; Van Zee KJ Ann Surg Oncol; 2016 Dec; 23(13):4253-4261. PubMed ID: 27766556 [TBL] [Abstract][Full Text] [Related]
25. Multiple foci of microinvasion is associated with an increased risk of invasive local recurrence in women with ductal carcinoma in situ treated with breast-conserving surgery. Rakovitch E; Sutradhar R; Lalani N; Nofech-Mozes S; Gu S; Goldberg M; Hanna W; Fong C; Paszat L Breast Cancer Res Treat; 2019 Nov; 178(1):169-176. PubMed ID: 31325071 [TBL] [Abstract][Full Text] [Related]
26. Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan. Yotsumoto D; Sagara Y; Kumamaru H; Niikura N; Miyata H; Kanbayashi C; Tsuda H; Yamamoto Y; Aogi K; Kubo M; Tamura K; Hayashi N; Miyashita M; Kadoya T; Saji S; Toi M; Imoto S; Jinno H Breast Cancer; 2022 Jan; 29(1):1-8. PubMed ID: 34665435 [TBL] [Abstract][Full Text] [Related]
27. Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study. Nguyen TT; Hoskin TL; Day CN; Habermann EB; Goetz MP; Boughey JC Ann Surg Oncol; 2017 Oct; 24(10):2989-2998. PubMed ID: 28766214 [TBL] [Abstract][Full Text] [Related]
28. Management of Ductal Carcinoma In Situ of the Breast: A Review. Shah C; Wobb J; Manyam B; Kundu N; Arthur D; Wazer D; Fernandez E; Vicini F JAMA Oncol; 2016 Aug; 2(8):1083-8. PubMed ID: 27253401 [TBL] [Abstract][Full Text] [Related]
29. Ductal Carcinoma In Situ: Treatment Update and Current Trends. Mitchell KB; Kuerer H Curr Oncol Rep; 2015 Nov; 17(11):48. PubMed ID: 26373411 [TBL] [Abstract][Full Text] [Related]
30. Radiotherapy and tamoxifen after breast-conserving surgery for DCIS. Cunnick GH; Mokbel K Int J Fertil Womens Med; 2004; 49(5):237-8. PubMed ID: 15633483 [TBL] [Abstract][Full Text] [Related]
31. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Fisher B; Dignam J; Wolmark N; Wickerham DL; Fisher ER; Mamounas E; Smith R; Begovic M; Dimitrov NV; Margolese RG; Kardinal CG; Kavanah MT; Fehrenbacher L; Oishi RH Lancet; 1999 Jun; 353(9169):1993-2000. PubMed ID: 10376613 [TBL] [Abstract][Full Text] [Related]
33. National Breast Cancer Audit: ductal carcinoma in situ management in Australia and New Zealand. Cuncins-Hearn A; Boult M; Babidge W; Zorbas H; Villanueva E; Evans A; Oliver D; Kollias J; Reeve T; Maddern G ANZ J Surg; 2007; 77(1-2):64-8. PubMed ID: 17295824 [TBL] [Abstract][Full Text] [Related]
34. Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy. Ciervide R; Dhage S; Guth A; Shapiro RL; Axelrod DM; Roses DF; Formenti SC Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e159-64. PubMed ID: 22579378 [TBL] [Abstract][Full Text] [Related]
35. Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study. Sprague BL; McLaughlin V; Hampton JM; Newcomb PA; Trentham-Dietz A Breast Cancer Res Treat; 2013 Aug; 141(1):145-54. PubMed ID: 23979007 [TBL] [Abstract][Full Text] [Related]
36. Controversies in the Treatment of Ductal Carcinoma in Situ. Barrio AV; Van Zee KJ Annu Rev Med; 2017 Jan; 68():197-211. PubMed ID: 28099081 [TBL] [Abstract][Full Text] [Related]
37. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. Vogel VG; Costantino JP; Wickerham DL; Cronin WM Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506 [TBL] [Abstract][Full Text] [Related]
38. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Cuzick J; Sestak I; Pinder SE; Ellis IO; Forsyth S; Bundred NJ; Forbes JF; Bishop H; Fentiman IS; George WD Lancet Oncol; 2011 Jan; 12(1):21-9. PubMed ID: 21145284 [TBL] [Abstract][Full Text] [Related]
39. Omitting radiation therapy after lumpectomy for pure DCIS does not reduce the risk of salvage mastectomy. Rakovitch E; Nofech-Mozes S; Hanna W; Sutradhar R; Gu S; Fong C; Tuck A; Youngson B; Miller N; Done SJ; Chang MC; Sengupta S; Elavathil L; Jani PA; Bonin M; Lalani N; Paszat L Breast; 2018 Feb; 37():181-186. PubMed ID: 28781102 [TBL] [Abstract][Full Text] [Related]
40. Ductal carcinoma in situ: a disease entity that merits more recognition. Dereere E; Papadimitriou K; Tjalma W; Altintas S Minerva Chir; 2015 Aug; 70(4):231-9. PubMed ID: 25916193 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]